Update on the Guidelines for Cervical Cancer Screening in Immunosuppressed Women

Program:

Faculty:

Lisa Flowers, MD, MPH; Professor in the Department of Obstetrics and Gynecology, Emory University School of Medicine; Atlanta, Georgia, USA

Dr. Lisa Flowers is a Professor in the Department of Obstetrics and Gynecology, Fellowship Director of the Lower Anogenital Screening and Treatment Fellowship, Director of the Colposcopy and Anoscopy clinics at Emory University Healthcare Systems and partners. She is a gynecologist specializing in HPV related cancers and health disparities especially in HIV populations. She has been a clinical specialist and translational researcher in the screening, detection and treatment of HPV related precancers and cancer. She is the Emory PI for the NCI Cervical Cancer ‘Last Mile’ Initiative, Self-collection for HPV testing to Improve Cervical Cancer Prevention (SHIP) Trial and the Emory PI for the NCI’s HIV/Cervical Cancer Prevention ‘CASCADE’ Clinical Trials Network, a cooperative agreement-funded program focused on pragmatic clinical trials to optimize the cervical cancer screening, management, and precancer treatment cascade for women living with HIV. She is also the Emory site Principal Investigator (PI) for the AIDS Malignancy Consortium (AMC) and site PI for the NIH/NCI multi-site study ANCHOR focusing on HPV related precancerous cells in women and men with HIV. She was awarded an R01 on oral microbiome and periodontal diseases in oral HPV infection among people living with HIV, R01 on screening strategies and social determinants of health among people with high risk of anal cancer and a U01 addressing community home-based education, screening services; strategy to increase cervical cancer control access for HIV positive women in Nigeria. Dr. Flowers is the Co-chair of the International Anal Neoplasia Society working group for implementation and dissemination of the newly developed anal cancer screening guidelines. She has over 26 years of experience in specializing in colposcopy in persons living with HPV related disease in both clinical and research settings.

Michael A. Gold, MD; Clinical Associate Professor in the Department of Obstetrics and Gynecology at University of Oklahoma School of Community Medicine; Tulsa, Oklahoma, USA

Dr. Gold, is a Clinical Associate Professor in the Department of Obstetrics and Gynecology at the University of Oklahoma School of Community Medicine. Dr. Gold specializes in gynecologic oncology and pelvic surgery. Dr. Gold received his medical degree from Jefferson Medical College in Philadelphia, PA. He completed his residency in gynecology and obstetrics at Thomas Jefferson University Hospital, also in Philadelphia. After residency, Dr. Gold completed his three-year fellowship in gynecologic oncology at the University of Oklahoma Health Sciences Center in Oklahoma City, where he remained on the faculty for nine years. He then moved to Vanderbilt University Medical Center, where he was the Director of the Division of Gynecologic Oncology. Dr. Gold’s clinical interests include the prevention and treatment of cervical cancer and pre-cancer (dysplasia) of the cervix, vagina, and vulva. He is active in clinical research focusing on gynecologic cancers in general and the imaging of cervical and uterine cancer, in particular. Dr. Gold is board certified by the American Board of Obstetrics and Gynecology, Division of Gynecologic Oncology. Dr. Gold is a Fellow of the American College of Obstetricians and Gynecologists and the American College of Surgeons. He is an active member of the Gynecologic Oncology Group, the Society of Gynecologic Oncologists, the American Society of Colposcopy and Cervical Pathology, and the American College of Radiology Imaging Network.

Barbara Moscicki, MD; Professor of Pediatrics at UCLA; Los Angeles, California, USA

Barbara Moscicki is Professor of Pediatrics at UCLA, Division Chief of Adolescent and Young Adult Medicine, and Associate Vice Chair of Clinical Research, Department of Pediatrics. Dr. Moscicki is Past President for the ASCCP. Dr. Moscicki’s career has focused on adolescent gynecology and sexually transmitted infection research with a specific focus in Human Papillomavirus, HIV infection and mucosal immunology. Dr. Moscicki has been the principle investigator of a natural history study of HPV in adolescents and young women since 1990, one of the longest running HPV cohorts. Her work was highly influential in forming the new cervical cancer screening guidelines and triage of abnormal cytology in young women. Her recent work focuses on mucosal immunology and the vaginal microbiota. She has been involved in numerous clinical trials including vaginal microbiocides and an ongoing one dose HPV vaccine trial. She is also involved in health outcomes in perinatally HIV infected children including HPV vaccine efficacy, sexual risk behaviors, substance use, oral health, microbiomes, and HPV infections and has worked with numerous Networks on HIV disease in children and adolescents including Adolescent Medicine HIV/AIDS Research Network, Adolescent Therapeutic Network, IMPAACT and PHACS. She has over 150 publications and she serves on numerous national and international committees, including the W.H.O., N.I.H., ASCCP, and the American Cancer Society.

Chair:

Jean-Luc Mergui, MD; France;
President, The International Federation of Cervical Pathology and Colposcopy (IFCPC)

Registration:

• IFCPC National Society Members: $0, free to members
• Non-Members: $15 US Dollars

• No refund or cancellation, all registrants will have access to the video archive.
  
• All prices are shown in US Dollars.
• The webinar will be presented in English with English captions; the video archive may be captioned in additional languages.